Abstract | BACKGROUND: METHODS AND RESULTS: Thirty 3-week-old piglets were randomized to placebo or sildenafil therapy 0.75 mg/kg TID after anastomosis of the left subclavian artery to the pulmonary arterial trunk or after a sham operation. Three months later, the animals underwent a hemodynamic evaluation followed by pulmonary tissue sampling for morphometry, immunohistochemistry or radioimmunoassay, and real-time quantitative-polymerase chain reaction. Chronic systemic-to-pulmonary shunting increased pulmonary mRNA for angiopoietin-1, endothelin-1 (ET-1), angiotensin II, inducible nitric oxide synthase, vascular endothelial growth factor, and PDE-5. Pulmonary messenger RNA for BMPR-1A and BMPR-2 decreased. Pulmonary angiotensin II, ET-1, and vascular endothelial growth factor proteins increased. Pulmonary artery pressure increased from 20+/-2 to 33+/-1 mm Hg, and arteriolar medial thickness increased by 91%. The expressions of angiopoietin-1, ET-1, and angiotensin II were tightly correlated to pulmonary hypertension. Sildenafil prevented the increase in pulmonary artery pressure, limited the increase in medial thickness to 41%, and corrected associated biological perturbations except for the angiopoietin-1/BMPR-2 pathway, PDE-5, and angiotensin II. CONCLUSIONS:
Sildenafil partially prevents overcirculation-induced PAH and associated changes in signaling molecules. Angiotensin II, PDE-5, and angiopoietin-1/BMPR-2 signaling may play a dominant role in the early stages of the disease.
|
Authors | Benoit Rondelet, François Kerbaul, Ronald Van Beneden, Sophie Motte, Pierre Fesler, Ives Hubloue, Myriam Remmelink, Serge Brimioulle, Isabelle Salmon, Jean-Marie Ketelslegers, Robert Naeije |
Journal | Circulation
(Circulation)
Vol. 110
Issue 15
Pg. 2220-5
(Oct 12 2004)
ISSN: 1524-4539 [Electronic] United States |
PMID | 15466636
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiopoietin-1
- Endothelin-1
- Phosphodiesterase Inhibitors
- Piperazines
- Purines
- RNA, Messenger
- Receptors, Growth Factor
- Sulfones
- Vascular Endothelial Growth Factor A
- Angiotensin II
- Sildenafil Citrate
- Nitric Oxide Synthase
- Nitric Oxide Synthase Type II
- Protein Serine-Threonine Kinases
- Bone Morphogenetic Protein Receptors, Type I
- Bone Morphogenetic Protein Receptors, Type II
- Phosphoric Diester Hydrolases
- 3',5'-Cyclic-GMP Phosphodiesterases
- Cyclic Nucleotide Phosphodiesterases, Type 5
|
Topics |
- 3',5'-Cyclic-GMP Phosphodiesterases
- Anastomosis, Surgical
(adverse effects)
- Angiopoietin-1
(biosynthesis, genetics, physiology)
- Angiotensin II
(biosynthesis, genetics)
- Animals
- Arterioles
(ultrastructure)
- Bone Morphogenetic Protein Receptors, Type I
- Bone Morphogenetic Protein Receptors, Type II
- Cyclic Nucleotide Phosphodiesterases, Type 5
- Drug Evaluation, Preclinical
- Endothelin-1
(biosynthesis, genetics)
- Gene Expression Regulation
(drug effects)
- Hyperplasia
- Hypertension, Pulmonary
(etiology, metabolism, prevention & control)
- Models, Animal
- Nitric Oxide Synthase
(biosynthesis, genetics)
- Nitric Oxide Synthase Type II
- Phosphodiesterase Inhibitors
(pharmacology, therapeutic use)
- Phosphoric Diester Hydrolases
(biosynthesis, drug effects, genetics)
- Piperazines
(pharmacology, therapeutic use)
- Protein Serine-Threonine Kinases
(biosynthesis, genetics, physiology)
- Pulmonary Artery
(surgery)
- Purines
- RNA, Messenger
(biosynthesis)
- Random Allocation
- Receptors, Growth Factor
(biosynthesis, genetics)
- Signal Transduction
(drug effects)
- Sildenafil Citrate
- Subclavian Artery
(surgery)
- Sulfones
- Sus scrofa
- Vascular Endothelial Growth Factor A
(biosynthesis, genetics)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|